Johnson & Johnson Inc. JNJ.nyse and Pfizer, Inc. PFE.nyse both announced they are stopping development of a drug to treat patients with mild to moderate Alzheimers after the drug failed a second clinical trial.
The companies both noted the drug, bapineuzumab, did not improve the condition of Alzheimer’s patients compared to a placebo.
The companies both noted the drug, bapineuzumab, did not improve the condition of Alzheimer’s patients compared to a placebo.
Aucun commentaire:
Enregistrer un commentaire